We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights UnitedHealth Group, Johnson & Johnson, Chevron, The Home Depot and AT&T
Read MoreHide Full Article
For Immediate Release
Chicago, IL – September 27, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: UnitedHealth Group Inc. (UNH - Free Report) , Johnson & Johnson (JNJ - Free Report) , Chevron Corp. (CVX - Free Report) , The Home Depot, Inc. (HD - Free Report) , and AT&T Inc. (T - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Stock Reports for UnitedHealth, Johnson & Johnson and Chevron
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Inc., Johnson & Johnson and Chevron Corp.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
UnitedHealth shares have outperformed the Zacks Medical - HMOs industry (+25.3% vs. +24.6%) and the S&P 500 (+25.3% vs. -18.1%) index over the past year . The Zacks analyst believes that the company's top line has been growing and the momentum should continue in the years ahead on the back of a strong market position and an attractive core business that continues to be driven by new deals, renewed agreements and expansion of service offerings.
UNH's Government business remains well-poised for growth. A sturdy balance sheet enables investments and prudent capital deployment through share buybacks and dividends. However, softness in commercial business due to COVID-induced volatilities persists. Also, the rising operating costs are hurting the company's bottom line.
Johnson & Johnson's shares have advanced +2.2% over the past year against the Zacks Large Cap Pharmaceuticals industry's gain of +6.0%. The Zacks analyst believes that J&J's diversification makes it relatively resilient amid macroeconomic turmoil. Its Pharma unit is performing at above-market levels, supported by its blockbuster drugs, Darzalex and Stelara, and contribution from newer drugs, Erleada and Tremfya. Sales in the MedTech unit are recovering in 2022 and the company is focusing on growing this business through new products. J&J is making rapid progress with its pipeline and line extensions.
However, sales in the Consumer and MedTech units are being hurt by inflationary pressure. Headwinds like generic competition and pricing pressure continue. Though J&J has taken meaningful steps to resolve its talc and opioid litigation, they continue to remain an overhang on the stock.
Chevron shares have outperformed the Zacks Oil and Gas - Integrated – International industry over the past year (+40.6% vs. +25.6%). The Zacks analyst believes that the company is considered one of the best-placed global integrated oil firms to achieve sustainable production ramp-up. America's No. 2 energy company's existing project pipeline is among the best in the industry, thanks to its premier position in the lucrative Permian Basin.
However, Chevron was not immune to the commodity price crash of 2020, forcing it to cut spending substantially. The company's high oil price sensitivity is a concern too. Moreover, the supermajor's 10-year reserve replacement ratio of 100% is indicative of its inability to replace the amount of oil and gas produced.
Other noteworthy reports we are featuring today include The Home Depot, Inc., and AT&T Inc..
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights UnitedHealth Group, Johnson & Johnson, Chevron, The Home Depot and AT&T
For Immediate Release
Chicago, IL – September 27, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: UnitedHealth Group Inc. (UNH - Free Report) , Johnson & Johnson (JNJ - Free Report) , Chevron Corp. (CVX - Free Report) , The Home Depot, Inc. (HD - Free Report) , and AT&T Inc. (T - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Stock Reports for UnitedHealth, Johnson & Johnson and Chevron
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Inc., Johnson & Johnson and Chevron Corp.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
UnitedHealth shares have outperformed the Zacks Medical - HMOs industry (+25.3% vs. +24.6%) and the S&P 500 (+25.3% vs. -18.1%) index over the past year . The Zacks analyst believes that the company's top line has been growing and the momentum should continue in the years ahead on the back of a strong market position and an attractive core business that continues to be driven by new deals, renewed agreements and expansion of service offerings.
UNH's Government business remains well-poised for growth. A sturdy balance sheet enables investments and prudent capital deployment through share buybacks and dividends. However, softness in commercial business due to COVID-induced volatilities persists. Also, the rising operating costs are hurting the company's bottom line.
(You can read the full research report on UnitedHealth here >>>)
Johnson & Johnson's shares have advanced +2.2% over the past year against the Zacks Large Cap Pharmaceuticals industry's gain of +6.0%. The Zacks analyst believes that J&J's diversification makes it relatively resilient amid macroeconomic turmoil. Its Pharma unit is performing at above-market levels, supported by its blockbuster drugs, Darzalex and Stelara, and contribution from newer drugs, Erleada and Tremfya. Sales in the MedTech unit are recovering in 2022 and the company is focusing on growing this business through new products. J&J is making rapid progress with its pipeline and line extensions.
However, sales in the Consumer and MedTech units are being hurt by inflationary pressure. Headwinds like generic competition and pricing pressure continue. Though J&J has taken meaningful steps to resolve its talc and opioid litigation, they continue to remain an overhang on the stock.
(You can read the full research report on Johnson & Johnson here >>>)
Chevron shares have outperformed the Zacks Oil and Gas - Integrated – International industry over the past year (+40.6% vs. +25.6%). The Zacks analyst believes that the company is considered one of the best-placed global integrated oil firms to achieve sustainable production ramp-up. America's No. 2 energy company's existing project pipeline is among the best in the industry, thanks to its premier position in the lucrative Permian Basin.
However, Chevron was not immune to the commodity price crash of 2020, forcing it to cut spending substantially. The company's high oil price sensitivity is a concern too. Moreover, the supermajor's 10-year reserve replacement ratio of 100% is indicative of its inability to replace the amount of oil and gas produced.
(You can read the full research report on Chevron here >>>)
Other noteworthy reports we are featuring today include The Home Depot, Inc., and AT&T Inc..
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.